UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response

Oncogene, 2010-08, Vol.29 (32), p.4517-4527

2010

Volltextzugriff (PDF)

WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation

Leukemia, 2009-09, Vol.23 (9), p.1634-1642

2009

Volltextzugriff (PDF)

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins

Cell death & disease, 2010-08, Vol.1 (8), p.e68-e68

2010

Volltextzugriff (PDF)

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2 HER2 peptide-based vaccination construct

British journal of cancer, 2005-04, Vol.92 (8), p.1421-1429

2005

Volltextzugriff (PDF)

Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition

Cell death and differentiation, 2006-04, Vol.13 (4), p.576-585

2006

Volltextzugriff (PDF)

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma

Oncoimmunology, 2022-12, Vol.11 (1), p.2127508-2127508

2022

Volltextzugriff (PDF)

The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells

Cell death and differentiation, 2007-09, Vol.14 (9), p.1678-1687

2007

Volltextzugriff (PDF)

A universal strategy for stable intracellular antibodies

Journal of immunological methods, 2005-08, Vol.303 (1), p.19-39

2005

Volltextzugriff (PDF)

A Novel Bispecific Tetravalent Antibody Fusion Protein to Target Costimulatory Activity for T-cell Activation to Tumor Cells Overexpressing ErbB2/HER2

Journal of molecular biology, 2005-03, Vol.346 (5), p.1299-1311

2005

Volltextzugriff (PDF)

P06.10.A CAR-ENGINEERED PRIMARY NK CELLS SHOW PROMISING EFFECTS AS TARGETED THERAPY AGAINST EGFR-POSITIVE GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii47-ii47

2023

Volltextzugriff (PDF)

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

Cancer Immunology, Immunotherapy, 2008-03, Vol.57 (3), p.411-423

2008

Volltextzugriff (PDF)

P06.06.B PD-1 CHECKPOINT INHIBITION IN CONJUNCTION WITH NK-92/5.28.Z CELLS IS EFFECTIVE IN AN ADVANCED-STAGE GLIOBLASTOMA MOUSE MODEL AND INDUCES A CD4-ENRICHED T CELL RESPONSE

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii46-ii46

2023

Volltextzugriff (PDF)

OS06.2A Local immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors in combination with CAR-NK cells

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii8-ii9

2021

Volltextzugriff (PDF)

OS12.6.A Combination therapy of CAR-NK-cells and anti-PD-1 results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii15-ii15

2021

Volltextzugriff (PDF)

P12.04 Synergistic effects of combination therapy of CAR-NK cells and anti-PD-1 antibody result in high efficacy against advanced stage orthotopic glioblastoma grafts in a syngeneic mouse model and induce protective anti-tumor immunity in vivo

Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii60-iii60

2019

Volltextzugriff (PDF)

P04.21 Combination therapy of CAR-NK cells and anti-PD-1 antibody displays potent efficacy against late-stage Glioblastoma and induces protective antitumor immunity

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii283-iii283

2018

Volltextzugriff (PDF)

P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2016-10, Vol.18 (suppl_4), p.iv24-iv25

2016

Volltextzugriff (PDF)

P07.01 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii51-iii52

2017

Volltextzugriff (PDF)

P06.13 A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells

Journal for immunotherapy of cancer, 2020-10, Vol.8 (Suppl 2), p.A47-A47

2020

Volltextzugriff (PDF)

Tracking of [18 F]FDG-labeled natural killer cells to HER2/neu-positive tumors

Nuclear medicine and biology, 2008-07, Vol.35 (5), p.579-588

2008

Volltextzugriff (PDF)

P06.12 Combination therapy of CAR-NK-cells and anti-PD-1 antibody results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

Journal for immunotherapy of cancer, 2020-10, Vol.8 (Suppl 2), p.A46-A47

2020

Volltextzugriff (PDF)

O6.05 ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (suppl 2), p.ii13-ii13

2014

Volltextzugriff (PDF)

ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-07, Vol.16 (suppl 3), p.iii44-iii44

2014

Volltextzugriff (PDF)

A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells

Journal of immunological methods, 2007-08, Vol.325 (1), p.140-147

2007

Volltextzugriff (PDF)

1 – 25 von 187

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(163)
Mit Volltextzugriff
(165)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(185)
Japanisch
(16)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response

WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2 HER2 peptide-based vaccination construct

Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma

The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells

A universal strategy for stable intracellular antibodies

A Novel Bispecific Tetravalent Antibody Fusion Protein to Target Costimulatory Activity for T-cell Activation to Tumor Cells Overexpressing ErbB2/HER2

P06.10.A CAR-ENGINEERED PRIMARY NK CELLS SHOW PROMISING EFFECTS AS TARGETED THERAPY AGAINST EGFR-POSITIVE GLIOBLASTOMA

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

P06.06.B PD-1 CHECKPOINT INHIBITION IN CONJUNCTION WITH NK-92/5.28.Z CELLS IS EFFECTIVE IN AN ADVANCED-STAGE GLIOBLASTOMA MOUSE MODEL AND INDUCES A CD4-ENRICHED T CELL RESPONSE

OS06.2A Local immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors in combination with CAR-NK cells

OS12.6.A Combination therapy of CAR-NK-cells and anti-PD-1 results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

P12.04 Synergistic effects of combination therapy of CAR-NK cells and anti-PD-1 antibody result in high efficacy against advanced stage orthotopic glioblastoma grafts in a syngeneic mouse model and induce protective anti-tumor immunity in vivo

P04.21 Combination therapy of CAR-NK cells and anti-PD-1 antibody displays potent efficacy against late-stage Glioblastoma and induces protective antitumor immunity

Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis

P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

P07.01 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

P06.13 A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells

Tracking of [18 F]FDG-labeled natural killer cells to HER2/neu-positive tumors

P06.12 Combination therapy of CAR-NK-cells and anti-PD-1 antibody results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

O6.05 ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells

Aktive Filter

Suchergebnisse filtern